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Introduction
Patients with small cell carcinoma of the prostate generally present 
with metastatic disease and have an estimated life expectancy measured 
in months. In this brief report, we present a case of rapidly progressive 
metastatic small cell carcinoma of the prostate in an octogenarian with 
significant response to split-dosed cisplatin and etoposide. This case 
report shows that cautious treatment with platinum-based regimens 
should still be considered in elderly patients given the potential 
for improvement in performance status and quality of life with 
chemotherapy. Additionally, this case highlights that platinum-based 
regimens are still considered the therapeutic backbone of prostate 
cancers with a mixed small cell carcinoma and adenocarcinoma 
phenotype.
Case report
An 81-year-old man with a history of Gleason 3+3 adenocarcinoma 
of the prostate diagnosed in 2006 and actively monitored with 
an annual prostate specific antigen (PSA) and digital rectal exam 
presented to the emergency department in March of 2016 with 1 
month of burning rectal pain. A CT scan demonstrated a 10.5 x 6.8 
x 8.1 cm fungating mass obscuring the prostate. Biopsy of the mass 
showed a CD56+/TTF1+/synaptophysin+/PSA-/PSAP-/ps501-/ERG- 
hyperchromatic high grade malignancy with nuclear molding necrosis 
and a high nuclear to cytoplasmic ratio consistent with small cell 
carcinoma (SCC) of the prostate (Figure 1). His PSA was 0.531 ng/mL 
at that time (Figure 2). He was started on chemotherapy with cisplatin 
and etoposide in May of 2016, but he experienced significant urinary 
retention and hematuria during cycle 1 which led to halting of therapy. 
In efforts to palliate his symptoms, he received 63 Gy of radiation over 
35 fractions to his pelvis with significant relief of his rectal pain. Repeat 
CT scan in October of 2016 showed interval decrease of the prostatic 
mass to 2.7 x 5.9 cm (Figure 3A). In November of 2016, he developed 
right axillary and pectoral swelling. CT scan of the chest revealed a 
13.1 x 7.2 cm right-sided, pleural-based mass invading the chest wall 
and causing destruction of the fifth rib with associated precarinal, 
subcarinal, perihilar, and axillary lymphadenopathy. Biopsy of the 
axillary lymph node showed small cell carcinoma identical to that seen 
in the prostate biopsy. PSA remained low at 0.176 ng/mL. The decision 
was made to restart chemotherapy in an attempt to improve functional 
status and quality of life. Given the patient’s advanced age and prior 
adverse event with chemotherapy, he was restarted on split-dose 
cisplatin 30 mg/m2 and etoposide 100 mg/m2, both administered on 
days 1-2 of 28-day cycles with a plan to complete 6 total cycles. Repeat 
CT scans following his second cycle of chemotherapy showed stable 
disease in his prostate with a significant reduction in size of his pleural-
based mass to 6.5 x 1.9 cm (Figure 3B). To date, he has received 3 cycles 
of cisplatin and etoposide with significant continued response and no 
serious side effects. 
Discussion
The prostate is one of the most common sites of extrapulmonary 
Figure 1. Small cell carcinoma (SCC) of the prostate (A and B hematoxylin & eosin, A: 
original magnification x100; B: original magnification x 200). 
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neuroendocrine carcinomas [1]. Neuroendocrine tumors of the prostate 
include conventional adenocarcinomas with focal differentiation, 
carcinoid tumors, tumors with Paneth cell-like neuroendocrine 
differentiation, large cell neuroendocrine carcinomas, and small 
cell carcinomas [1,2]. While focal neuroendocrine differentiation is 
identified in most prostatic adenocarcinomas, SCC of the prostate is a 
less commonly occurring entity seen in 0.5 – 2% of men diagnosed with 
prostate cancer. It is characterized by pronounced prostatic enlargement 
with a disproportionately low PSA, unresponsiveness to androgen 
deprivation therapy (ADT), and a rapidly progressive course with 
frequent visceral metastases and lytic bone lesions [2,3]. In descending 
order of frequency, men with prostatic SCC most commonly present 
with voiding, neurologic (confusion, sensory/motor deficits), and/or 
constitutional symptoms [3]. SCC of the prostate arises in men with 
pre-existing adenocarcinoma who have received androgen deprivation 
in nearly half of cases [2,4,5]. This is believed to occur either due to 
adaptive dedifferentiation of malignant cells under the influence of 
ADT or the selective pressures of ADT favoring the proliferation of 
androgen receptor negative neuroendocrine cells [4].
The diagnosis of prostatic SCC can be made without tissue if the 
patient’s clinical presentation is convincing and their functional status 
precludes therapeutic delays [2,6]. Histological examination of prostatic 
SCC is indistinguishable from SCC originating from other sites of the 
body. Pathological findings include rows of small cells with a high 
nuclear: cytoplasmic ratio, increased mitotic rates, coarse chromatin, 
necrosis, nuclear molding, and inconspicuous nucleoli [7]. Prostatic 
SCC can either be characterized as having a classical oat cell morphology 
(scant cytoplasm, open chromatin, small nuclei) or intermediate cell 
morphology (abundant cytoplasm, occasional nucleoli, large nuclei) 
[8]. Prostatic SCC’s of the intermediate cell variant, in particular, 
can look morphologically similar to poorly differentiated Gleason 5 
adenocarcinoma. Since these two entities have different therapeutic 
strategies, it is important to perform immunohistochemistry in all 
poorly differentiated specimens to identify the proper diagnosis 
[7]. A complete immunohistochemical panel including prostatic 
markers (PSA, PSAP, PSMA, ps501) and neuroendocrine markers 
(CD56, TTF-1, synaptophysin, and chromogranin) will be able to 
provide supplemental diagnostic information. Most prostatic SCCs 
will be negative or focally positive for prostatic markers, while poorly 
differentiated adenocarcinomas will be diffusely positive [8]. 
In situations such as the current case presentation where 
pathological specimens reveal small cell carcinoma in two separate sites 
of the body, it can be difficult to determine which region of the body the 
primary arose from. It is necessary to combine immunohistochemistry 
with clinical presentation to facilitate making an accurate diagnosis. 
Any positivity with prostatic markers, regardless of intensity, is 
highly suggestive of prostatic origin. CD44 and ERG are particularly 
specific for tumors of prostatic origin8. However, most prostatic 
SCC’s are pan-negative for prostatic markers, which makes prostatic 
marker expression an unreliable discriminatory tool [8]. In addition, 
up to 50% of prostatic SCC’s are TTF-1 positive, making this cellular 
marker unreliable in differentiating between pulmonary and prostatic 
primaries as well [9]. In this patient’s case, the prostate was identified 
as the primary based on the temporal progression of clinical symptoms 
given that the immunohistochemical analysis was non-specific. 
SCC of the prostate is an aggressive malignancy associated with a 
poor prognosis. An analysis of 191 cases of prostatic SCC registered 
in the Surveillance, Epidemiology, and End Results (SEER) database 
between 1973 and 2003 showed a median survival of 11 months, while 
patients over the age of 75 had a median survival of only 6 months 
[10]. The majority of patients present with metastatic disease. The 
most common sites of metastases are the bones, retroperitoneal lymph 
nodes, liver, lungs, and brain [4]. Therapeutic strategies are largely 
derived from experience with small cell lung cancer and retrospective 
reviews as data from randomized controlled trials with prostatic SCC 
is limited. Localized control with either a prostatectomy or radiation 
therapy should be considered in patients with limited stage disease as it 
has been associated with improved outcomes in retrospective reviews 
[10,11]. For patients who present with advanced disease, systemic 
chemotherapy with a platinum-based agent combined with either 
etoposide or docetaxel is the mainstay of therapy [6]. Radiotherapy can 
Figure 2. Prostate specific antigen (PSA) levels over time. Green arrow: PSA level at 
time of prostatic SCC diagnosis. Red Arrow: PSA level at time of metastatic progression 
following radiation therapy.
Figure 3. Top Row: CT scan of the pelvis demonstrating SCC of the prostate prior to 
radiation therapy (Figure 3A
1
 - 10.5 x 6.8 x 8.1 cm) and following radiation therapy (Figure 
3A
2
 – 2.7 x 5.9 cm). Bottom Row: CT scan of the chest demonstrating metastatic SCC of 
the prostate prior to chemotherapy (Figure 3B
1
 – 13.1 x 7.2 cm) and following 2 cycles of 
split-dose cisplatin/etoposide (Figure 3B
2
 – 6.5 x 1.9 cm).
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be used as needed for palliation of symptoms [2]. 
Conclusion
In this report, an octogenarian with rapidly progressive metastatic 
SCC of the prostate had a significant response to split-dosed cisplatin 
and etoposide combination chemotherapy. This case report shows 
that cautious treatment with platinum-based regimens should still be 
considered in elderly patients given the potential for improvement in 
performance status and quality of life with chemotherapy. Furthermore, 
patients with mixed SCC and adenocarcinoma of the prostate should 
still receive platinum-based regimens as first-line therapy, although 
androgen deprivation therapy is sometimes given concurrently 
depending on the phenotype of the mixed disease [2]. Despite our 
patient’s excellent response, the course of the malignancy is such that 
he will likely relapse. While there is no effective second-line therapy 
established currently, novel agents being investigated in patients with 
neuroendocrine prostate cancer, such as aurora kinase A (AURKA) 
and poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors, might have 
promising activity in this patient population whose therapeutic options 
are limited [12-15].     
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